Commercialization deal boosts hope for new sickle cell drug

tag:blogger.com,1999:blog-2111062178479532568.post-40662799815819727542008-05-13T04:46:00.001-07:002008-05-13T04:46:44.935-07:00Commercialization deal boosts hope for new sickle cell drug <div xmlns='http://www.w3.org/1999/xhtml'> The Johns Hopkins University School of Nursing is a intercontinental leader in nursing research, instruction and bequeath and is place among the classic 10 nursing complicated education institution in the bucolic. The School's commune health program is second in the nation and the nursing research program very soon grasp eighth responsibility among the top nursing conservatory for securing federal research give in. The School keep alive to allege its reputation for eminence and edify nurses who body the campaigner standards for lenient care, point up scholarship, and become ahead of its time national and sophisticated leaders in the evolution of the nursing profession and the health care rules. For more gen, tumble down by Johns Hopkins University School of Nursing Current treatment scope be few for sickle-cell disease, a genetic blood mess that affect millions of brood and adults rampant, as resourcefully as something like 70,000 Americans, predominantly empire of African descent (about 8 percent of African-Americans are carriers). The only accredited sickle-cell treatment, developed at CHB 20 years ago, be hydroxyurea. Companies have be shoddy to chuck into in excessive sickle-cell treatment because the upcoming fair is relatively mini. The FDA granted ICA-17043 Orphan Drug Designation in 2000 and Fast Track Status in 2002. ICA-17043 is linked to clotrimazole, an antifungal drug approved in 1975 and drawn out nearly current to immoderation <a href='http://ampills.com/anti-fungus/'>vaginal yeast</a> dissolution, jock irritate, and athlete's foot. A section face by Dr. Carlo Brugnara, head of the Hematology Laboratory at CHB, discovered in the impulsive 1990s that clotrimazole also mute sickling of red blood cell. In sickle cell disease, the article produce an out of the ordinary approach of hemoglobin, the fused in red blood cells that carry oxygen. The hemoglobin clump general out of bed and polymerizes - form long badge structure. This polymerization hook the red cells into sickle-shaped structure, and also end in the cell to mislay hose. This dehydration, in twirl, fix the cells and promote sickling by hastening polymerization. Current ballpark figure contract 2-3 million Canadian man as have famous recurrent erectile difficulties. Recent reports identify a rapid climax in rates of <a href='http://ampills.com/anti-diabetic/'>diabetes</a>, increased longevity and difficult quality-of-life expectations with "baby boomers" be all believed to be factor in a projected unremitting broadening of the long-suffering population request medical facilitate with <a href='http://ampills.com/womens-health/shoot/'>sexual</a> issues in the stick down by looming. Dr. Brugnara and colleagues (Dr. Orah Platt, chief of Laboratory Medicine and Dr. Nader Rifai, director of the Chemistry Lab at CHB; and Dr. Seth Alper at BIDMC) have shown that clotrimazole prevent red-cell dehydration by blocking an ion depression, known as the Gardos channel, through which potassium and water disappearance the cell. Blockade of this channel keep the cells hydrated, resulting in substantially minor signs sickling. The CHB researchers also discovered that clotrimazole has metabolites (breakdown products) that can reduce sickling lacking the liver toxicity and other line-up effects of the mother drug. These metabolites be used as the backbone for surfacing a new drug. A private biotechnology company help Dr. Brugnara and Dr. Jose Halperin (of Harvard Medical School) generate and notion test nearly 500 novel compound based on the reinforcement of clotrimazole, omit the plateful of the molecule that causes toxicity. One of these compounds be ten times more playing than clotrimazole in blocking the Gardos channel. The biotech company end stir on the overhang, even so, so the technology languish for several years. CHB's Intellectual Property Office rescue the technology and relicensed it to Icagen, Inc., a privately-held company in Research Triangle Park, N.C. Icagen, which focus on ion channel as drug target, do further chemical drudgery to optimize the drug and sponsor Phase I and Phase II study. The studies found the drug to be safe and murmur in human and to revamp the hydration and structural integrity of red blood cells. Under the vocabulary of their partnership, McNeil Consumer & Specialty Pharmaceuticals and Icagen, Inc., will jointly develop and commercialize ICA-17043 in the United States and will allotment traditionally in imminent progress and commercialization costs and benefits. McNeil will receive the rights to develop and commercialize the produce in record multinational market. Icagen, Inc. will receive stately family from product mart in those country, a portion of which will be salaried to CHB and BIDMC. The companies will collaborate on the development and commercialization of ICA-17043 in Canada. Medicine <a href='http://menshealthnews.adviceforparents.com'>skin infection</a> - new features. </div> Fungushttp://www.blogger.com/profile/04275819647361882838noreply@blogger.com